Graham Capital Management
RIGL icon

Graham Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Graham Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$471K Sell
12,050
-1,843
-13% -$56.8K 0.01% 731
2026
Q1 		$376K Sell
13,893
-7,074
-34% -$238K 0.01% 719
2025
Q4 		$898K Sell
20,967
-2,518
-11% -$94.9K 0.02% 421
2025
Q3 		$665K Buy
23,485
+6,731
+40% +$201K 0.01% 513
2025
Q2 		$314K Buy
16,754
+1,597
+11% +$30.3K ﹤0.01% 982
2025
Q1 		$273K Buy
15,157
+5,071
+50% +$103K ﹤0.01% 1030
2024
Q4 		$170K Buy
+10,086
New +$193K ﹤0.01% 1103
2024
Q2 		– Sell
-3,662
Closed -$54.2K – 1311
2024
Q1 		$54.2K Sell
3,662
-267
-7% -$3.6K ﹤0.01% 1008
2023
Q4 		$57K Buy
3,929
+921
+31% +$9.42K ﹤0.01% 936
2023
Q3 		$32.5K Sell
3,008
-5,163
-63% -$62.1K ﹤0.01% 972
2023
Q2 		$105K Buy
8,171
+7,040
+622% +$95.2K ﹤0.01% 886
2023
Q1 		$14.9K Buy
+1,131
New +$18K ﹤0.01% 1016
2022
Q4 		– Sell
-93,529
Closed -$1.1M – 1297
2022
Q3 		$1.1M Buy
93,529
+81,364
+669% +$1.1M 0.04% 443
2022
Q2 		$137K Sell
12,165
-16,321
-57% -$328K 0.01% 947
2022
Q1 		$851K Buy
28,486
+20,137
+241% +$545K 0.03% 368
2021
Q4 		$221K Buy
+8,349
New +$252K 0.01% 435

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's RIGL Position: Q2 2026 in Review

Graham Capital Management reduced its Rigel Pharmaceuticals (RIGL) stake by 13% in Q2 2026, selling an estimated $56.8K and leaving 12,050 shares worth $471K. The position accounts for 0.01% of the portfolio, ranked #731.

Graham Capital Management first reported a position in RIGL in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.1M in Q3 2022. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Graham Capital Management held 12,050 shares of Rigel Pharmaceuticals worth $471K as of Q2 2026.
  • Graham Capital Management sold 1,843 Rigel Pharmaceuticals shares in Q2 2026, an estimated $56.8K.
  • Rigel Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #731 holding.
  • Graham Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2021 and has held it in 16 quarters since.
  • Graham Capital Management's Rigel Pharmaceuticals position peaked at $1.1M in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.